Receive ADMET case studies from Genentech, F. Hoffmann-La Roche, J&J, AstraZeneca, GSK, UCB, Janssen, Novartis and more

Top Quote SMi's 10th annual ADMET conference will discuss the latest advancements in AMDET-enabling technologies with an array of case study driven presentations. End Quote
  • (1888PressRelease) June 09, 2015 - SMi's 10th annual ADMET conference will feature case studies from Genentech, Roche, AstraZeneca, GSK, UCB, Janssen, Novartis, Johnson & Johnson and Vertex Pharmaceuticals among others, who will be providing insight of the latest technologies being utilised, metabolomics, predictive toxicology and ADME/Tox screening at early stages of drug discovery where the development process has become even more crucial.

    This year's two-day conference agenda will build on the success of the 2014 event by addressing:
    • In vitro models and technologies for detecting cardiotoxicity
    • Performance analysis of different in vitro models to detect human hepatotoxic drugs
    • Human stem cell derived cardiomyocytes
    • Regulatory DDI guidance for drug transporters - an overview review of current FDA, EMA and JMHLW (Japan) guidance for industry
    • Mitigating errors in early human dose predictions and setting the criteria for ADME end points

    Attend SMi's 10th annual ADMET conference to:
    • Receive 17 case studies from speakers representing both the pharma and biotech industries addressing the development of human cellular models and state-of-the-art in vitro used to assess toxicity, plus over 3 hours of networking sessions discussing and analysing the latest novel technologies being used in the field of Predictive Toxicology and ADME/Tox
    • Network with a global audience of leading scientists and key decision makers in the ADMET arena. Confirmed attendees include: Boehringer Ingelheim, Astex Pharmaceuticals, Orion Corporation, Orion Pharma, Xenotech LLC, University Of Basel, Polyphor Ltd, plus many more

    Key Speakers include:
    • Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutica
    • Professor Ian D. Wilson, Professor of Drug Metabolism, Imperial College London
    • Laurent Salphati, Senior Scientist, Genentech
    • Thierry Lave, Global Head DMPK & Tox Project Leaders and Modelling & Simulation, F. Hoffmann-La Roche
    • Peter Clements, Director of Pathology, GSK
    • Stephen Fowler, Group Leader, In Vitro ADME, F. Hoffmann-La Roche
    • Franck Atienzar, Associate Director In Silico In Vitro Toxicology, UCB BioPharma SPRL
    • Peter Hoffmann, Executive Director, Pre-Clinical Safety, Novartis Institutes for BioMedical Research
    • Mario Monshouwer, Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis, Johnson & Johnson

    To view the full speaker line-up and conference programme, visit http://www.admet-event.com/1888pressrelease

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
  • Vinh Trinh
  • Smi Group
  • Unit 122/124 Great Guildford Business Square, 30 Great Guildford Street, London
  • SE1 0HS
  • Voice: 44 (0) 20 7827 6140
  • Visit our Site